Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:45 2026-04-13 am EDT			5-day change	1st Jan Change
120.62 ^CHF	-0.94%		-2.09%	+10.05%

Apr. 10	Health Care Down on Retreat from Biotech -- Health Care Roundup	DJ
Apr. 10	NOVARTIS AG : UBS reiterates its Neutral rating	ZD

Novartis AG Approves Board and Committee Appointments

Published on 03/06/2026 at 09:21 am EST

S&P Capital IQ

NOVARTIS AG

-0.94%

Novartis AG announced at the AGM held on March 6, 2026, approved elected Charles Swanton as new member of the Board of Directors. Daniel Hochstrasser did not stand for re-election. Elected Elizabeth McNally as new member of the Compensation Committee, each until the end of the next AGM.

Latest news about Novartis AG

Apr. 10	Health Care Down on Retreat from Biotech -- Health Care Roundup	DJ
Apr. 10	NOVARTIS AG : UBS reiterates its Neutral rating	ZD
Apr. 09	European Stocks Mostly Lower in Thursday Trading; Oil Prices Rise as Ceasefire on Shaky Ground	MT
Apr. 09	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Fragile Middle East Ceasefire Lifts Oil Prices	MT
Apr. 09	Novartis to Expand Community Health Programs to More Countries	MT
Apr. 09	Novartis Plans Expansion to 30 Countries of Community Health Programs	MT
Apr. 09	Novartis announces expansion of community health programs to close gaps in heart disease and cancer care	RE
Apr. 09	Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030	DJ
Apr. 09	Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030	DJ
Apr. 09	Novartis Announces Expansion of Community Health Programs to Close Gaps in Heart Disease and Cancer Care	CI
Apr. 02	Global pharma companies that have publicly announced Trump drug pricing agreements	RE
Mar. 31	NOVARTIS AG : Goldman Sachs remains a Sell rating	ZD
Mar. 31	Drugmakers delay some European launches with a wary eye on Trump's pricing policies	RE
Mar. 30	Wall Street ends mostly lower as Middle East conflict weighs	RE
Mar. 30	European Stocks Track Higher in Monday Trading; German Inflation Surges	MT

Chart Novartis AG

Duration

Period

NOVN: Dynamic Chart

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Apr. 28 - Earnings release - Q1 2026

More about the company